Safety and Feasibility of Chimeric Antigen Receptor T Cell Therapy After Allogeneic Hematopoietic Cell Transplantation in Relapsed/ Refractory B Cell Non-Hodgkin Lymphoma

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2019 May 23

PMID 31114023

Citations 17

Authors

Tania Jain

Craig S Sauter

Gunjan L Shah

Molly A Maloy

Jason Chan

Michael Scordo

Scott T Avecilla

Yakup Batlevi

Parastoo B Dahi

Connie W Batlevi

M Lia Palomba

Sergio A Giralt

Miguel-Angel Perales

Affiliations

Soon will be listed here.

Citing Articles

Long-term remission following CAR-T therapy in a patient with transformed follicular lymphoma relapse after allogeneic stem cell transplantation.

Kubo R, Onodera K, Onishi Y, Fukuhara N, Harigae H Ann Hematol. 2024; 104(1):841-845.

PMID: 39738826 DOI: 10.1007/s00277-024-06150-8.

Mitigating and managing infection risk in adults treated with CAR T-cell therapy.

Tabbara N, Dioverti-Prono M, Jain T Hematology Am Soc Hematol Educ Program. 2024; 2024(1):116-125.

PMID: 39644015 PMC: 11706248. DOI: 10.1182/hematology.2024000535.

Too short or unnecessarily long: walking the fine line.

Sainatham C, Jain T Blood Adv. 2024; 8(20):5430-5432.

PMID: 39405073 PMC: 11526071. DOI: 10.1182/bloodadvances.2024013812.

Sclerotic chronic cutaneous graft-versus-host-disease following pseudoallogeneic chimeric antigen receptor T-cell therapy.

Choi E, Nguyen C JAAD Case Rep. 2024; 52:42-45.

PMID: 39286820 PMC: 11403442. DOI: 10.1016/j.jdcr.2024.06.014.

Novel Approaches to Treatment of Acute Myeloid Leukemia Relapse Post Allogeneic Stem Cell Transplantation.

Liberatore C, Di Ianni M Int J Mol Sci. 2023; 24(19).

PMID: 37834466 PMC: 10573608. DOI: 10.3390/ijms241915019.

References

Fraietta J, Beckwith K, Patel P, Ruella M, Zheng Z, Barrett D . Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016; 127(9):1117-27. PMC: 4778162. DOI: 10.1182/blood-2015-11-679134. View

Hirayama A, Gauthier J, Hay K, Voutsinas J, Wu Q, Gooley T . The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood. 2019; 133(17):1876-1887. PMC: 6484391. DOI: 10.1182/blood-2018-11-887067. View

Miklos D, Cutler C, Arora M, Waller E, Jagasia M, Pusic I . Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017; 130(21):2243-2250. PMC: 6033048. DOI: 10.1182/blood-2017-07-793786. View

Cruz C, Micklethwaite K, Savoldo B, Ramos C, Lam S, Ku S . Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013; 122(17):2965-73. PMC: 3811171. DOI: 10.1182/blood-2013-06-506741. View

Schuster S, Svoboda J, Chong E, Nasta S, Mato A, Anak O . Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N Engl J Med. 2017; 377(26):2545-2554. PMC: 5788566. DOI: 10.1056/NEJMoa1708566. View

Perales M, Kebriaei P, Kean L, Sadelain M . Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR. Biol Blood Marrow Transplant. 2017; 24(1):27-31. PMC: 5901894. DOI: 10.1016/j.bbmt.2017.10.017. View

Lee D, Santomasso B, Locke F, Ghobadi A, Turtle C, Brudno J . ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2018; 25(4):625-638. DOI: 10.1016/j.bbmt.2018.12.758. View

Jacoby E, Yang Y, Qin H, Chien C, Kochenderfer J, Fry T . Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD. Blood. 2015; 127(10):1361-70. PMC: 4786842. DOI: 10.1182/blood-2015-08-664250. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

10.

Ghosh A, Smith M, James S, Davila M, Velardi E, Argyropoulos K . Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nat Med. 2017; 23(2):242-249. PMC: 5528161. DOI: 10.1038/nm.4258. View

11.

Kebriaei P, Singh H, Huls M, Figliola M, Bassett R, Olivares S . Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest. 2016; 126(9):3363-76. PMC: 5004935. DOI: 10.1172/JCI86721. View

12.

Brudno J, Somerville R, Shi V, Rose J, Halverson D, Fowler D . Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. J Clin Oncol. 2016; 34(10):1112-21. PMC: 4872017. DOI: 10.1200/JCO.2015.64.5929. View

13.

Lee D, Kochenderfer J, Stetler-Stevenson M, Cui Y, Delbrook C, Feldman S . T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2014; 385(9967):517-528. PMC: 7065359. DOI: 10.1016/S0140-6736(14)61403-3. View

14.

Ruella M, Kenderian S, Shestova O, Fraietta J, Qayyum S, Zhang Q . The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clin Cancer Res. 2016; 22(11):2684-96. DOI: 10.1158/1078-0432.CCR-15-1527. View

15.

Wilson W, Young R, Schmitz R, Yang Y, Pittaluga S, Wright G . Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015; 21(8):922-6. PMC: 8372245. DOI: 10.1038/nm.3884. View

16.

Park J, Riviere I, Gonen M, Wang X, Senechal B, Curran K . Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):449-459. PMC: 6637939. DOI: 10.1056/NEJMoa1709919. View

17.

Neelapu S, Locke F, Bartlett N, Lekakis L, Miklos D, Jacobson C . Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017; 377(26):2531-2544. PMC: 5882485. DOI: 10.1056/NEJMoa1707447. View